March 13, 2018 / 4:59 PM / in 9 months

BRIEF-Valneva Initiates Phase I Clinical Study Of Vaccine Candidate Against Chikungunya

March 13 (Reuters) - VALNEVA SE:

* REG-VALNEVA INITIATES PHASE I CLINICAL STUDY TO EVALUATE ITS SINGLE-SHOT VACCINE CANDIDATE AGAINST CHIKUNGUNYA

* PHASE I CLINICAL TO INVESTIGATE THREE DIFFERENT DOSE LEVELS OF VLA1553 IN AROUND 120 HEALTHY ADULTS VACCINATED WITH A SINGLE-SHOT IMMUNIZATION

* FIRST DATA FROM TRIAL ARE EXPECTED TO BE AVAILABLE EARLY 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below